Description
CJC-1295 with DAC (also designated DAC:GRF) is a synthetic peptide belonging to the growth hormone secretagogue (GHS) class, engineered as a modified analogue of endogenous growth hormone-releasing hormone (GHRH) [1]. Developed from the biologically active GHRH(1-29) fragment, the molecule incorporates several amino acid substitutions that confer greater resistance to enzymatic degradation compared to the native sequence [1].
The compound's most distinctive structural feature is the Drug Affinity Complex (DAC) moiety, a maleimidopropionic acid-based modification that enables covalent binding to circulating serum albumin. This albumin-binding property extends the peptide's functional half-life from a matter of minutes — typical of unmodified GHRH analogues — to several days in biological matrices, producing a markedly prolonged pharmacokinetic profile [1].
Because of this extended activity window, CJC-1295 with DAC is employed in laboratory settings to investigate sustained growth hormone (GH) signaling and downstream insulin-like growth factor 1 (IGF-1) modulation. Researchers apply it in preclinical models to probe GH pulse dynamics, GH-related metabolic pathways, lipid metabolism, and cellular processes associated with prolonged GH/IGF-1 axis activation.
The sustained-release characteristics of the DAC modification make this compound particularly useful in studies where maintaining consistent GH pathway stimulation over extended observation periods is a methodological requirement, allowing investigators to assess long-duration biological responses that would otherwise be difficult to capture using shorter-acting GHRH peptides.
---
References
[1] CJC-1295. Wikipedia. https://en.wikipedia.org/wiki/CJC-1295
